Update on the Alison Yowell Story
The Washington Post and WRC-TV 4 in Washington report this morning that Loudoun County Superintendant Hatrick has offered to rehire Alison Yowell after her treatment for Hodgkin's Lymphoma.
I had written Mr. Hatrick and others stating that the treatment sounded harsh given Ms. Yowell was undergoing cancer treatment. He wrote back stating the media had not portrayed all of the story - the school district could not go into detail since Ms. Yowell had not given them permission to do so.
Still this is not so great for Alison as she lost her health insurance and will be out of pocket for treating her cancer.
The school district has stated they will look at their leave policies but it appears all parties involved may not be in agreement on changing things.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
